St. Jude Medical (STJ) Risk from Dear Doctor Letter is Limited, Cowen Says
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Cowen analyst Joshua Jennings weighed in on St. Jude Medical (NYSE: STJ) after the company issued a voluntary medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio (ICDs and CRT-Ds).
"Although these Dear Doctor letters are never a positive, it is common in the Cardiac Rhythm Management industry," Jennings said. "We see the risk to STJ's franchise as limited. We still anticipate that the ABT/ STJ transaction will close by the end of the year."
The firm maintained a Outperform rating and price target of $85
Shares of St. Jude Medical closed at $81.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransDigm (TDG) Valeant Comparison 'Nothing New', Tweet Risk Low and Would Use Weakness to Buy - Credit Suisse
- Stocks with call price movement; BIIB TDG
- Generics File Against New Teva Pharma (TEVA) Copaxone 40MG Patent - Evercore ISI
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Short Sales, Trader Talk
Related EntitiesCowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!